MGNX: Antibody Drug Conjugate Progress Will Drive Future Upside Potential

Analysts have lifted their price target on MacroGenics to $6.75 from $3.75, citing updated assumptions on revenue trends, profitability and a lower expected P/E multiple, as well as recent positive research following the Tubulis deal and ongoing antibody drug conjugate progress.

Analyst Commentary

Bullish Takeaways

Bullish analysts point to the higher price targets as a reflection of updated assumptions on revenue trends and profitability, suggesting they see the current valuation as more aligned with their revised models.
Recent research tied to the Tubulis transaction is viewed as a key support for higher expectations around MacroGenics' antibody drug conjugate pipeline, which some analysts see as a meaningful growth driver if execution stays on track.
The focus on antibody drug conjugate progress, including future data readouts, is cited as a potential upside catalyst that could justify a higher P/E multiple if clinical and commercial milestones are met.
Analysts highlighting the raised price targets frame the stock as more fairly priced relative to their view of execution on partnerships, development timelines and potential revenue contribution from new assets.

Bearish Takeaways

Bearish analysts emphasize that the higher targets still reflect a lower expected P/E multiple, which signals some caution around the predictability of earnings and the timing of profitability.
There is concern that a meaningful portion of the upside case rests on future antibody drug conjugate data, which introduces clinical and regulatory execution risk that could affect valuation if results or timelines differ from expectations.
Ongoing reliance on deal related momentum, such as the Tubulis agreement, is seen as a risk factor if partnership economics, milestones or integration do not track current assumptions.
Some cautious views focus on the possibility that revenue and margin trends may be slower or more uneven than modeled, which would limit the scope for multiple expansion and keep the stock more sensitive to individual data and deal updates.

What's in the News

U.S. FDA removed the partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab in gynecologic cancers, allowing new participant enrollment under a revised protocol with additional risk-mitigation measures for potential hematologic and cardiac toxicities (Key Developments).
The LINNET study is set to evaluate single agent lorigerlimab, which targets PD-1 and CTLA-4, in up to approximately 60 eligible participants with platinum resistant ovarian cancer or clear cell gynecologic cancer, with objective response rate as the primary endpoint and multiple secondary endpoints (Key Developments).
To date, 41 participants have been dosed in the LINNET study and over 300 participants have been dosed across all previous lorigerlimab Phase 1 and Phase 2 clinical studies, highlighting the current clinical experience with the drug candidate (Key Developments).
Earlier, the U.S. FDA had placed a partial clinical hold on the Phase 2 LINNET study after safety events across four patients, including Grade 4 thrombocytopenia, Grade 4 myocarditis, and Grade 4 neutropenia with concurrent septic shock that led to a Grade 5 event, which initially paused new enrollment (Key Developments).

Valuation Changes

Fair Value: The updated target fair value has risen significantly from $3.75 to $6.75 per share.
Discount Rate: The discount rate has fallen from 8.41% to 7.29%, indicating a lower required return in the updated model.
Revenue Growth: The forecast revenue trend shows a smaller decline, moving from a 20.05% expected drop to a 2.52% expected drop.
Profit Margin: The assumed net profit margin has risen from 14.17% to 18.87% in the revised estimates.
Future P/E: The assumed future P/E multiple has fallen from 25.52x to 19.43x, indicating a lower valuation multiple in the new framework.

0 views

Key Takeaways

Future revenue growth potential hinges on successful trial outcomes and product approvals in ongoing and upcoming clinical studies.
A robust pipeline and financial sustainability support continued R&D efforts, reinforcing prospects for growth if new treatments prove effective.
Rising R&D costs, potential liquidity risks, and strategic shifts in program development highlight financial and operational challenges for MacroGenics.

Catalysts

About MacroGenics

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.What are the underlying business or industry changes driving this perspective?

Completion of enrollment in the LORIKEET Phase 2 trial for lorigerlimab, with anticipated updates in the second half of 2025, could drive investor expectations for future revenue growth if promising clinical results are obtained.
Initiation of the LINNET Phase 2 study in mid-2025, targeting unmet needs in ovarian and gynecologic cancers, positions MacroGenics for potential future earnings improvement if successful trial outcomes lead to product approvals.
The promising clinical development of MGC026, an ADC targeting B7-H3, with potential dose expansion planned for 2025, suggests future revenue potential if the treatment shows efficacy and safety in solid tumors.
The ongoing Phase 1 trial for MGC028 and the anticipated IND submission for MGC030 in 2026 indicate a robust pipeline that could enhance revenue and earnings if these drugs prove effective and secure regulatory approval.
The $201.7 million cash balance, anticipated to support operations into the second half of 2026, underscores the company’s ability to sustain its R&D activities, enhancing future revenue potential from successful product development.

MacroGenics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming MacroGenics's revenue will decrease by 2.5% annually over the next 3 years.
Analysts are not forecasting that MacroGenics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate MacroGenics's profit margin will increase from -44.8% to the average US Biotechs industry of 18.9% in 3 years.
If MacroGenics's profit margin were to converge on the industry average, you could expect earnings to reach $27.5 million (and earnings per share of $0.42) by about May 2029, up from -$70.4 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.6x on those 2029 earnings, up from -4.0x today. This future PE is greater than the current PE for the US Biotechs industry at 16.2x.
Analysts expect the number of shares outstanding to grow by 0.57% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.29%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

MacroGenics reported a net loss of $67 million for the year-ended December 31, 2024, compared to a net loss of $9.1 million for 2023, which could impact future earnings and overall financial health.
The company's research and development expenses increased to $177.2 million in 2024 from $166.6 million in 2023, indicating rising costs that could pressure net margins and profitability.
MacroGenics is exploring alternatives for partnering its vobra duo program after deciding not to pursue further internal development, which reflects uncertainty in generating future revenue from this asset.
The company anticipates that its cash reserves and future partner payments will support operations only until the second half of 2026, indicating potential liquidity risks and dependency on successful future collaborations or funding.
The ongoing clinical trials and development of new candidates are subject to the usual risks associated with clinical research, including unpredictable outcomes and approval challenges, which could impact future revenue streams.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $6.75 for MacroGenics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $9.0, and the most bearish reporting a price target of just $4.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $145.5 million, earnings will come to $27.5 million, and it would be trading on a PE ratio of 19.6x, assuming you use a discount rate of 7.3%.
Given the current share price of $4.46, the analyst price target of $6.75 is 33.9% higher. Despite analysts expecting the underlying business to decline, they seem to believe it's more valuable than what the market thinks.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on MacroGenics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

LORIKEET And LINNET Trials Will Spur Advances Amid Liquidity Risks